For the first quarter of the fiscal year ending March 2027, the results show YoY changes in revenue and each income item, but specific figures are not disclosed. The main body includes explanations of changes in key indicators and an overview of the financial position. The quarterly financial status details are presented in sections ‘Assets’ and ‘Liabilities’ and ‘Net assets’. The fiscal year includes a partial comparison table for the 2026 fiscal year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4538","jir_company_name":"Fus\u014d Pharmaceutical Industry Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4538-20260810-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending March 2027, the results show YoY changes in revenue and each income item, but specific figures are not disclosed. The main body includes explanations of changes in key indicators and an overview of the financial position. The quarterly financial status details are presented in sections 'Assets' and 'Liabilities' and 'Net assets'. The fiscal year includes a partial comparison table for the 2026 fiscal year.","jir_summary":"### Section Heading\nThis Financial Summary is structured around the Overview of Operating Results and the Quarterly Financial Statements and Key Notes, summarizing the performance and financial position for the first quarter of the fiscal year ending March 2027. The trends in revenue and profit for the first quarter against the previous year are shown in a comparison table, but the PDF does not disclose numeric figures, so exact amounts are unknown. Figures for assets, liabilities, and net assets are provided in the attached balance sheet and notes, illustrating the soundness of the capital structure. Note that depreciation and other items are also included in the notes as additional information.\n\n### Section 2 Heading\nFactors affecting the outlook and performance include trends in the pharmaceutical business, raw material price movements, exchange rate effects, and capital expenditure policy. The quarterly financial statements provide details on the factors behind changes in assets and liabilities, cash and deposits, receivables and payables breakdown, and fixed asset status, offering shareholders material information on financial soundness. Regarding future outlook, it may refer to comparisons with the full-year plan and potential revisions, but the document itself does not state specific figures.","jir_financial_highlights":"Revenue: Unknown (YoY unknown)\nCost of revenue: Unknown (YoY unknown)\nOperating income: Unknown (YoY unknown)\nOrdinary income: Unknown (YoY unknown)\nTotal net assets: Unknown (YoY unknown)","jir_category":"","jir_hashtags":"#Fus\u014dPharmaceuticalIndustry, #FinancialSummary, #QuarterlyFinancialStatements, #FinancialStatements","jir_key_figures":"Revenue: Unknown\nCost of revenue: Unknown\nOperating income: Unknown","jir_meta_title":"Fus\u014d Pharmaceutical Industry FY2027 Q1 Financial Summary | Revenue and Profit Details Unknown","jir_meta_description":"Analysis of Fus\u014d Pharmaceutical Industry's FY2027 Q1 Financial Summary. Specific values are not disclosed in the PDF. Explanations of the breakdown of assets, liabilities, and net assets, notes, and future outlook factors.","jir_og_title":"Fus\u014d Pharmaceutical Industry | FY2027 Q1 Financial Summary","jir_og_description":"Analysis of Fus\u014d Pharmaceutical Industry's Q1 Financial Summary. Official numeric values for revenue and profit are unknown, but provides an overview of the financial statement structure and notes.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":57749,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-101068","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n